Here, we sought to understand which molecular pathways changed in skin tissue in response to therapeutic blockade of IL-6 signaling in the context of two clinical trials, and how that information could be extrapolated to potentially address the unmet need in SSc. This evidence concerns the gene IL6 and systemic sclerosis.